Linkedin
RLS logo_header
Linkedin

Fujifilm and Taiho Pharmaceutical Enter into Strategic Partnership for Development of Next-Gen ADC Manufacturing Technologies

FUJIFILM Corporation and Taiho Pharmaceutical announced that they have entered into a strategic partnership agreement for the development of manufacturing technologies for next-generation antibody-drug conjugates. Under this partnership, the two companies will work to optimize manufacturing processes for ADC candidates being developed by Taiho Pharmaceutical using the AraLinQ™ technology of Araris Biotech AG, a subsidiary of Taiho Pharmaceutical. By combining Taiho Pharmaceutical’s expertise and capabilities in ADC drug discovery with Fujifilm’s process development and manufacturing technologies cultivated through its biologics CDMO* business, the companies aim to achieve stable production of high-quality ADCs and enhance their global competitiveness in the next-generation ADC field.

Read the full story on "Fujifilm and Taiho Pharmaceutical Enter into Strategic Partnership for Development of Next-Gen ADC Manufacturing Technologies"

Share:

More News

Olomorasib receives FDA Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer

“Pancreatic cancer has historically been one of the most difficult-to-treat cancers and people whose tumors harbor a KRAS G12C mutation face limited options once their disease progresses,” said Jacob Van Naarden, executive vice president, and president of Lilly Oncology. “This Breakthrough Therapy designation reflects the early potential we’re seeing with

Ratio Therapeutics Closes $70 Million Series C Financing to Advance Clinical Development of Radiotherapeutics Pipeline and Expand Manufacturing Infrastructure

“This financing reflects the confidence our investors and strategic partners have in the progress we have made to date and the opportunities that lie ahead,” said Dr. Jack Hoppin, Chief Executive Officer of Ratio Therapeutics. “As we march the ATLAS trial forward and prepare for our 5th IND filing, these

IDE892 Initiates Part 2 Monotherapy Expansion in Ph 1/2 Study in MTAP-Deleted Pancreatic & Lung Cancers

“We are excited to initiate monotherapy expansion evaluating IDE892 in MTAP-deleted PDAC and NSCLC. We designed IDE892 to be a potential best-in-class PRMT5 inhibitor, including approximately 1,400-fold selective MTA-PRMT5 cooperative binding versus SAM-PRMT5 cooperative binding, lack of brain penetrance, and favorable drug-like properties intended to maximize its therapeutic window as

FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer Announced

“The data presented at ASCO provided important insight into the potential clinical path for CRB-701 in 2L oropharyngeal cancer, a distinct tumor-type that is on the rise due to HPV infections,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “Unfortunately, current treatment options have shown limited efficacy underscoring the